• Search
  • Helpdesk
  • Sales contact

Rare Disease case study

Last updated : May 7, 2025

Over 90% of rare diseases have no treatment… 

  • There are more than 6,000 known rare diseases…
  • Approximately 80% of them have a genetic component… 75% affect children…
  • And most rare diseases are chronic conditions, many of which progress overtime and are potentially fatal…

Understanding the rare disease framework is key to be able to offer study participants adapted solutions and as such, positively contribute to important and necessary clinical research conducted on rare diseases.

Kayentis offers an extensive experience in rare disease clinical trials, in indications such as:

  • Prader-Willi Syndrome
  • PIK3CA-related overgrowth spectrum
  • Auto-Immune Hepatitis (AIH)
  • Hypoparathyroidism
  • Sjögren’s syndrome
  • Acute Vertigo

Download the case study 👇
Follow us on social media
Subscribe to our newsletter
About the author
Meet us at the following events

5th Annual Clinical Trial Innovation Summit

JUNE 26, 2025 • Basel, CH
Clinical Trial Innovation Summit 2025 | June 26, 2025

The reckless value of Patient Reported Outcomes (PROs) for Emerging Biopharma Companies – Webinar

July 9 • 11-12AM EDT / 4-5PM GMT / 5-6PM CET
In today’s competitive landscape, biotech and emerging biopharma companies (EBPs) must demonstrate the value of their innovations early and convincingly....

DPHARM 2025

SEPT 16-17 2025 • Philadelphia, PA, USA
Booth #44 16th Annual Outsourcing in Clinical Trials East Coast 2025 - Arena International